Back to Authors

Luskin, Marlise R

0000-0002-5781-4529

A5023296232 | I4210117453

Mayo Clinic

Dana-Farber Cancer Institute

Citations 21

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

Blood | January 11, 2016 | Volume: 127 | Issue: 12 | Pages: 1551-1558

10.1182/blood-2015-07-657403 | PMID 26755712

Key Points High-dose daunorubicin benefits AML patients with favorable and intermediate cytogenetics and with FLT3-ITD, NPM1, and DNMT3A mutations. High-dose daunorubicin is required for the favorable impact of the NPM1 mutation in AML.